These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
720 related articles for article (PubMed ID: 26717038)
21. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309 [TBL] [Abstract][Full Text] [Related]
22. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337 [TBL] [Abstract][Full Text] [Related]
23. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib. Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085 [TBL] [Abstract][Full Text] [Related]
24. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Coscia M; Pantaleoni F; Riganti C; Vitale C; Rigoni M; Peola S; Castella B; Foglietta M; Griggio V; Drandi D; Ladetto M; Bosia A; Boccadoro M; Massaia M Leukemia; 2011 May; 25(5):828-37. PubMed ID: 21372840 [TBL] [Abstract][Full Text] [Related]
25. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Reiff SD; Muhowski EM; Guinn D; Lehman A; Fabian CA; Cheney C; Mantel R; Smith L; Johnson AJ; Young WB; Johnson AR; Liu L; Byrd JC; Woyach JA Blood; 2018 Sep; 132(10):1039-1049. PubMed ID: 30018078 [TBL] [Abstract][Full Text] [Related]
26. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells. Till KJ; Pettitt AR; Slupsky JR J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006 [TBL] [Abstract][Full Text] [Related]
27. A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia. Wiśniewski K; Puła B Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791284 [TBL] [Abstract][Full Text] [Related]
32. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Lampson BL; Brown JR Expert Rev Hematol; 2018 Mar; 11(3):185-194. PubMed ID: 29381098 [TBL] [Abstract][Full Text] [Related]
33. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Rushworth SA; Murray MY; Zaitseva L; Bowles KM; MacEwan DJ Blood; 2014 Feb; 123(8):1229-38. PubMed ID: 24307721 [TBL] [Abstract][Full Text] [Related]
34. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698 [TBL] [Abstract][Full Text] [Related]
35. Targeting BTK through microRNA in chronic lymphocytic leukemia. Bottoni A; Rizzotto L; Lai TH; Liu C; Smith LL; Mantel R; Reiff S; El-Gamal D; Larkin K; Johnson AJ; Lapalombella R; Lehman A; Plunkett W; Byrd JC; Blachly JS; Woyach JA; Sampath D Blood; 2016 Dec; 128(26):3101-3112. PubMed ID: 27756747 [TBL] [Abstract][Full Text] [Related]
36. Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. Rigoni M; Riganti C; Vitale C; Griggio V; Campia I; Robino M; Foglietta M; Castella B; Sciancalepore P; Buondonno I; Drandi D; Ladetto M; Boccadoro M; Massaia M; Coscia M Oncotarget; 2015 Oct; 6(30):29833-46. PubMed ID: 26284584 [TBL] [Abstract][Full Text] [Related]
37. Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function. Ren L; Campbell A; Fang H; Gautam S; Elavazhagan S; Fatehchand K; Mehta P; Stiff A; Reader BF; Mo X; Byrd JC; Carson WE; Butchar JP; Tridandapani S J Biol Chem; 2016 Feb; 291(6):3043-52. PubMed ID: 26627823 [TBL] [Abstract][Full Text] [Related]
38. Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia. Li PP; Lu K; Geng LY; Zhou XX; Li XY; Wang X Mol Med Rep; 2016 Jun; 13(6):4934-8. PubMed ID: 27082823 [TBL] [Abstract][Full Text] [Related]
39. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164 [TBL] [Abstract][Full Text] [Related]
40. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Herman SE; Mustafa RZ; Gyamfi JA; Pittaluga S; Chang S; Chang B; Farooqui M; Wiestner A Blood; 2014 May; 123(21):3286-95. PubMed ID: 24659631 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]